A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid

被引:18
作者
He, Xiao-Long [1 ]
Wang, Li-Ting [1 ]
Gu, Xiang-Zhong [2 ]
Xiao, Jie-Xin [1 ]
Qiu, Wen-Wei [1 ]
机构
[1] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Chem Engn, Shanghai 200241, Peoples R China
[2] Jiangsu Jiaerke Pharmaceut Grp Co Ltd, Dept Res & Dev, Zhenglu Town 213111, Changzhou, Peoples R China
关键词
Ursodeoxycholic acid; Obeticholic acid; Cholic acid; Synthesis; PRIMARY BILIARY-CIRRHOSIS; NONALCOHOLIC FATTY LIVER; DISEASE; STEATOHEPATITIS; THERAPIES; AGONIST; POTENT; NASH;
D O I
10.1016/j.steroids.2018.10.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A novel synthetic route of producing ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) was developed through multiple reactions from cheap and readily-available cholic acid. The reaction conditions of the key elimination reaction of mesylate ester group were also investigated and optimized, including solvent, base and reaction temperature. In the straightforward synthetic route for preparation of UDCA and OCA, most of the reaction steps have high conversions with average yields of 94% and 92%, and overall yield up to 65% (7 steps) and 36% (11 steps) from cholic acid, respectively. This promising route offers economical and efficient strategies for potential large-scale production of UDCA and OCA.
引用
收藏
页码:173 / 178
页数:6
相关论文
共 40 条
[1]   Biotransformation of methyl cholate by Aspergillus niger [J].
Al-Aboudi, Amal ;
Mohammad, Y. Mohammad ;
Haddad, Salim ;
Al-Far, Rawhi ;
Choudhary, M. Iqbal ;
Atta-ur-Rahman .
STEROIDS, 2009, 74 (4-5) :483-486
[2]   Obeticholic acid for the treatment of primary biliary cholangitis [J].
Ali, Ahmad H. ;
Lindor, Keith D. .
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (13) :1809-1815
[3]   Bile acids: regulation of apoptosis by ursodeoxycholic acid [J].
Amaral, Joana D. ;
Viana, Ricardo J. S. ;
Ramalho, Rita M. ;
Steer, Clifford J. ;
Rodrigues, Cecilia M. P. .
JOURNAL OF LIPID RESEARCH, 2009, 50 (09) :1721-1734
[4]   Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid [J].
Boberg, K. M. ;
Wisloff, T. ;
Kjollesdal, K. S. ;
Stovring, H. ;
Kristiansen, I. S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (07) :794-803
[5]   NASH: A glance at the landscape of pharmacological treatment [J].
Brodosi, Lucia ;
Marchignoli, Francesca ;
Petroni, Maria Letizia ;
Marchesini, Giulio .
ANNALS OF HEPATOLOGY, 2016, 15 (05) :673-681
[6]   The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J].
Buzzetti, Elena ;
Pinzani, Massimo ;
Tsochatzis, Emmanuel A. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08) :1038-1048
[7]  
Cao J.S., 2010, Patent No. [102464692 [P], 102464692]
[8]   Treatment of PBC-A step forward [J].
Carbone, Marco ;
Invernizzi, Pietro .
LIVER INTERNATIONAL, 2017, 37 (04) :503-505
[9]   Old and new treatments for primary biliary cholangitis [J].
Chascsa, David ;
Carey, Elizabeth J. ;
Lindor, Keith D. .
LIVER INTERNATIONAL, 2017, 37 (04) :490-499
[10]   The NASH drug dash [J].
Chi, Kelly Rae .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (07) :447-448